🌱 KidneyEnergy.com

← brief for 2026-11-15 · Slowing decline

ADVANCES IN NEPHROPROTECTIVE THERAPY IN CHRONIC KIDNEY DISEASE: THE ROLE OF SGLT2 INHIBITORS AND FINERENONE

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This review summarizes large trials showing that SGLT2 inhibitors and finerenone protect the kidneys. These drugs slow kidney decline and lower heart risks. The evidence is strong because it comes from big, well-run studies.

Who did this work

Xakimova I.T. (Andijan State Medical Institute) · Worldly Knowledge Publishing Centre

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-11-14
https://doi.org/10.5281/zenodo.24218624